# Eli Lilly's Tough Month: Bank Predicts 37% Gains

> Citi forecasts 37% stock gains for Eli Lilly as selloff ends.
- Title: Eli Lilly's Tough Month: Bank Predicts 37% Gains | Shortify
- Summary: Citi forecasts 37% stock gains for Eli Lilly as selloff ends. Citi predicts Eli Lilly's stock could rise 37% by year-end due to obesity drug pipeline…
- Keywords: eli lilly, citi, glp-1, mounjaro, zepbound, retatrutide, medicare bridge program, obesity market, stock price target, wall street, Eli, Lilly's
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/09/22/eli-lillys-tough-month-one-of-the-biggest-global-banks-says-37-gains-begin-soon
- Author: Alex Sirois
- Published: 2026-09-22T11:34:21+00:00
- Read time: 1 min
- Topics: eli lilly, citi, glp-1, mounjaro, zepbound, retatrutide, medicare bridge program, obesity market, stock price target, wall street
## Eli Lilly's Q2 Results Crush Estimates
Eli Lilly's Q2 revenue beat consensus by 11.06% and EPS came in 27.27% above estimates.
## Stock Drops 7.21% Despite Strong Results
Lilly shares dropped 7.21% over the past month, sliding from $1,255.40 to current levels.
## Wall Street's Price Target Gap
Eli Lilly trades at $1,164.79 versus Wall Street's average target of $1,325.39, leaving 14% implied upside.
## Citi's 37% Upside Case
Citi's Geoff Meacham targets $1,600 for Eli Lilly, implying 37% gains from current levels.
## Obesity Market Dominance
Lilly dominates the GLP-1 obesity and diabetes market with Mounjaro and Zepbound generating $14.9 billion quarterly.
## Pricing Pressures on Lilly
Realized U.S. prices fell 9% excluding rebates, and international pricing compressed after Mounjaro's inclusion in China's National Reimbursement Drug List.
## Citi's Bull Case for 2027
Citi expects retatrutide to clear FDA by Q1 2027, with Foundayo maintaining inflection and Medicare Bridge Program expanding access.
## Key takeaway

Citi predicts Eli Lilly's stock could rise 37% by year-end due to obesity drug pipeline advancements.